AstraZeneca shares soar on Pfizer interest
By DANICA KIRKA - AP - 23 mins ago
LONDON (AP) — Shares in Anglo-Swedish drugmaker AstraZeneca jumped 15 percent on Monday after U.S. pharmaceutical firm Pfizer said it offered to buy the company for around $100 billion.
European Stocks Rise; AstraZeneca Jumps on Renewed Pfizer Interest
at The Street - 27 mins ago
Growing tensions in Ukraine cast a pall over Europe and Asia on Monday but the pharmaceuticals industry delivers more strong medicine and markets in Europe are recovering.
Global Refractory Multiple Myeloma Global Clinical Trials Review 2014
M2 - 2 hrs 50 mins ago
Research and Markets (http://www.researchandmarkets.com/research/gphksg/refractory) has announced the addition of the "Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" report to their offering. Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" provides data on the Refractory Multiple Myeloma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Multiple Myeloma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Multiple Myeloma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles of Top Companies/Organisations - Celgene Corporation - Amgen Inc. - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Novartis AG - Merck & Co., Inc. - F. Hoffmann-La Roche Ltd. - Pfizer Inc. - Bristol-Myers Squibb Company - AbbVie Inc. - National Cancer Institute - Fred Hutchinson Cancer Research Center - Mayo Clinic - The University of Texas M. D. Anderson Cancer Center - University of Arkansas - Case Comprehensive Cancer Center - Memorial Sloan Kettering Cancer Center - City of Hope National Medical Center - Washington University School of Medicinea For more information visit http://www.researchandmarkets.com/research/gphksg/refractory
Pfizer Confirms Prior Discussions with AstraZeneca Regarding a Possible Combination and Its Continuing Interest in a Possible Merger Transaction
Business Wire - Mon Apr 28, 1:08AM CDT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Should These 3 Stingy Stocks Pay Higher Dividends?
Dan Caplinger, The Motley Fool - Motley Fool - Sun Apr 27, 10:35AM CDT
The S&P 500 is a fruitful place to look for stocks that pay solid dividends. But even when a stock has an attractive dividend yield, one question you should always ask is whether that dividend is sustainable. Sometimes, you'll find that a high...
Say Hello to 3 Existing and Upcoming Next-Generation Blockbuster Drugs
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 26, 12:26PM CDT
Investing in biopharmaceutical stocks can be an uphill battle from day one. For example, Medscape notes that of any 5,000 to 10,000 drugs investigated in a preclinical setting, only one will make it to pharmacy shelves . That's an extremely high...
What Formula Brings Success for This Infant Formula Maker?
Mark Lin, The Motley Fool - Motley Fool - Sat Apr 26, 10:00AM CDT
Source: Mead Johnson While there are many publicly traded food & beverage companies, few can match the stellar financial track record of infant nutrition company Mead Johnson Nutrition . It has been profitable in every single year of the...
IBD 50: Actavis, Spirit Lead 5 Top Earnings On Tap
at Investor's Business Daily - Sat Apr 26, 7:02AM CDT
The market is in correction with tensions in Ukraine weighing on sentiment, but several top-rated companies are slated to report earnings this week. Most of these stocks are holding up relatively well. Spirit Airlines (SAVE), ranked No. 2 on the IBD...
Can Biogen Dethrone Baxter in Hemophilia?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 25, 5:30PM CDT
Drugmakers like Biogen are enjoying a new wave of success as they usher next-generation therapies to market that are displacing prior treatments. Gilead has de-throned injectible drugs as the standard of care with a faster and better working...
FDA reviews psychiatric side effects of Chantix
By MATTHEW PERRONE - AP - Fri Apr 25, 4:35PM CDT
WASHINGTON (AP) — The Food and Drug Administration announced Friday it will hold a public meeting in October to review the risks of psychiatric and behavioral side effects with Pfizer's anti-smoking drug Chantix.
Teva's Copaxone: Perspectives From a Patient and Investor
Anders Bylund, The Motley Fool - Motley Fool - Fri Apr 25, 1:30PM CDT
I was diagnosed with multiple sclerosis five years ago. My neurologist asked me to choose one of the classic CRAB (Copaxone, Rebif, Avonex, or Betaseron) therapies, and I settled on Teva Pharmaceutical Industries ' blockbuster Copaxone treatment....
3 Questions About a Big Pharma Megamerger
Seth Robey, The Motley Fool - Motley Fool - Fri Apr 25, 1:30PM CDT
It's been hard to miss the action in Big Pharma this week, as some of the most established drug makers engaged in a series of acquisition, merger, and asset swap rumors. A buyout of English company AstraZeneca by American powerhouse Pfizer was...
Why This Huge Dividend Stock Has Snoozed Through 2014
Dan Carroll, The Motley Fool - Motley Fool - Fri Apr 25, 1:30PM CDT
Pfizer 's one of big pharma's most recognizable names, and this Dow Jones member's recognized as one of the tried-and-true dividend giants among the market's blue-chip health-care stocks. Yet this company's had to fight back the patent cliff's...
Midday Glance: Pharmaceuticals companies
AP - Fri Apr 25, 12:23PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Fri Apr 25, 9:32AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
AstraZeneca Misses Earnings But Up on Takeover Rumors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 9:30AM CDT
AstraZeneca's first-quarter 2014 core earnings of $1.17 per American Depositary Share missed the Zacks Consensus Estimate of $1.20.
This Is Dividend Stock Johnson & Johnson’s Major Weakness
Peter Stephens, The Motley Fool - Motley Fool - Fri Apr 25, 8:30AM CDT
In a previous article on J&J , I highlighted the company's major strengths -- and it has many, not least of which is its 2.7% dividend yield. Now it's time to focus on its major weakness. Diversity: A double-edged sword While J&J's...
Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT) and Express Scripts Holding Company (NASDAQ: ESRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1586-100free.
Pfizer to pay USD0.26 dividend for Q2 2014
M2 - Fri Apr 25, 5:09AM CDT
The board of directors of Pfizer (NYSE
Drugmakers' Q1 was anemic
at Investor's Business Daily - Thu Apr 24, 5:36PM CDT
Citing R&D and marketing costs, AstraZeneca (AZN) missed EPS estimates with a 17% drop to $1.17. Flat sales of $6.4 bil did beat views. Eli Lilly (LLY) met EPS views of 70 cents, but sales fell 16% to $4.7 bil. Novartis (NVS) EPS slid 3% to $1.28,...